Reporting of Complications in Rhinoplasty Randomized Controlled Trials: An Analysis Using the CONSORT Extension for Harms Checklist

被引:0
|
作者
Hemmerich, Christian [1 ,7 ]
Corcoran, Adam [2 ]
Johnson, Austin L. [3 ]
Wilson, Andrew [1 ]
Orris, Olivia [4 ]
Arellanes, Russell [5 ]
Vassar, Matt [1 ,6 ]
机构
[1] Oklahoma State Univ, Dept Med Res, Ctr Hlth Sci, Tulsa, OK USA
[2] Mclaren Oakland, Dept Otolaryngol, Detroit, MI USA
[3] Univ Texas Med Branch, Dept Otolaryngol, Galveston, TX USA
[4] Philadelphia Coll Osteopath Med, Dept Med Res, Philadelphia, PA USA
[5] Oklahoma State Univ, Med Ctr, Dept Otolaryngol, Tulsa, OK USA
[6] Oklahoma State Univ, Ctr Hlth Sci, Dept Psychiat & Behav Sci, Tulsa, OK USA
[7] Oklahoma State Univ, Dept Med Res, Ctr Hlth Sci, 1111 W 17th St, Tulsa, OK 74107 USA
关键词
CONSORT-Harms; facial plastic and reconstructive surgery; patient safety; rhinoplasty;
D O I
10.1002/ohn.765
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
ObjectiveThis study aimed to assess the completeness of adverse event (AE) reporting in randomized control trials (RCTs) focused on rhinoplasty, using the Consolidated Standards for Reporting (CONSORT) Extension for Harms checklist.Study DesignA cross-sectional design was employed to review RCTs related to rhinoplasty published between January 1, 2005, and January 28, 2022.SettingThe study analyzed clinical trials on rhinoplasty retrieved from PubMed.MethodsWe performed a comprehension search on PubMed, blind and duplicate screening, and data extraction. Adherence to the 18 recommendations of the CONSORT Extension for Harms was evaluated, with 1 point assigned for each adhered item. Percent adherence was calculated based on the 18 points, taking into account the multiple subcategories within some recommendations. Descriptive statistics were used to summarize adherence-including frequencies, percentages, and 95% confidence intervals.ResultsOur search returned 240 articles, of which 56 met inclusion criteria. No RCTs adhered to all 18 CONSORT Extension for Harms items. Twenty-six (26/56, 46.4%) adhered to >= 50% of the items, and 30 (30/56, 53.6%) adhered to >= 33.3% of the items. Seven (7/56, 12.5%) RCTs adhered to no items. Across all RCTs, the average number of CONSORT-Harms items adhered to was 7.2 (7.2/18, 40.0%). The most adhered to item was item 10. Discussion balanced with regard to efficacy and AEs (80.4%, [70.0-90.8]).ConclusionThis study highlights the inadequacy of AE reporting in rhinoplasty RCTs according to CONSORT-Harms guidelines. Urgent efforts are required to bridge this reporting gap and enhance transparency in surgical research, ultimately safeguarding patient well-being.
引用
收藏
页码:81 / 89
页数:9
相关论文
共 50 条
  • [11] CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration
    Kwakkenbos, Linda
    Imran, Mahrukh
    McCall, Stephen J.
    McCord, Kimberly A.
    Frobert, Ole
    Hemkens, Lars G.
    Zwarenstein, Merrick
    Relton, Clare
    Rice, Danielle B.
    Langan, Sinead M.
    Benchimol, Eric, I
    Thabane, Lehana
    Campbell, Marion K.
    Sampson, Margaret
    Erlinge, David
    Verkooijen, Helena M.
    Moher, David
    Boutron, Isabelle
    Ravaud, Philippe
    Nicholl, Jon
    Uher, Rudolf
    Sauve, Maureen
    Fletcher, John
    Torgerson, David
    Gale, Chris
    Juszczak, Edmund
    Thombs, Brett D.
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2021, 373
  • [12] Reporting of Harms by Randomized Controlled Trials in Ophthalmology
    O'Day, Roderick
    Walton, Richard
    Blennerhassett, Richard
    Gillies, Mark C.
    Barthelmes, Daniel
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
  • [13] Erratum to: Methods and processes for development of a CONSORT extension for reporting pilot randomized controlled trials
    Lehana Thabane
    Sally Hopewell
    Gillian A. Lancaster
    Christine M. Bond
    Claire L. Coleman
    Michael J. Campbell
    Sandra M. Eldridge
    [J]. Pilot and Feasibility Studies, 2 (1)
  • [14] CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials
    Junqueira, Daniela R.
    Zorzela, Liliane
    Golder, Susan
    Loke, Yoon
    Gagnier, Joel J.
    Julious, Steven A.
    Li, Tianjing
    Mayo-Wilson, Evan
    Pham, Ba
    Phillips, Rachel
    Santaguida, Pasqualina
    Scherer, Roberta W.
    Gotzsche, Peter C.
    Moher, David
    Ioannidis, John P. A.
    Vohra, Sunita
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2023, 158 : 149 - 165
  • [16] Reporting of randomized controlled trials as per CONSORT guidelines
    Misra, Puneet
    Jha, Shreya
    Misra, Anoop
    Kant, Shashi
    [J]. JOURNAL OF FAMILY MEDICINE AND PRIMARY CARE, 2022, 11 (10) : 6598 - 6598
  • [17] Reporting randomized controlled trials in gastroenterology: The CONSORT statement
    Sandler, RS
    [J]. GASTROENTEROLOGY, 2001, 121 (04) : 755 - 755
  • [18] Reporting of noninferiority and equivalence randomized trials - An extension of the CONSORT Statement
    Piaggio, G
    Elbourne, DR
    Altman, DG
    Pocock, SJ
    Evans, SJW
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (10): : 1152 - 1160
  • [20] CONSORT 2010 statement: extension checklist for reporting within person randomised trials
    Pandis, Nikolaos
    Chung, Bryan
    Scherer, Roberta W.
    Elbourne, Diana
    Altman, Douglas G.
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2017, 357